Thank you Ascendis Pharma U.S. for inviting us for these two very important occasions, for continuing to keep us in the conversation and the opportunity to meet with Pamela Gavin. Congrats on your award and your beautiful new office.
Today, in the #AscendisPharma Princeton office, the President and CEO of the National Organization for Rare Disorders (NORD) was onsite to present Ascendis with the 2025 NORD Rare Impact Award for developing and delivering the first FDA-approved therapy for #hypoparathyroidism. Leaders from the HypoPARAthyroidism Association joined this celebration, making the milestone even more meaningful. Adding to the excitement of the day, our patient advocacy guests along with members of the New Jersey biotech and business communities gathered with our team for an official Princeton office ribbon cutting. ✂️ Since 2024, the Ascendis U.S. workforce has more than doubled, creating jobs, fostering collaboration, and fueling innovation to better serve people with rare conditions. Today’s celebrations and milestones mark an important time for Ascendis Pharma and showcase our continued commitment to improving the lives of people living with rare #endocrinology conditions. 💙 #LifeAtAscendis #NewBeginnings #TeamWork #OfficeOpening #PatientFocused #InnovationInAction #RareImpactAward